TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02345499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy with open urinary diversion
Description: Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cystectomy with open urinary diversion
Description: Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
Study: NCT02267031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg.
Study: NCT01979640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 39 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 37 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 35 Fr double lumen tube group
Description: additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
Study: NCT00752895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT02735720

Intervention type: OTHER
Intervention: TEVAR
Description: Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.

Intervention type: OTHER
Intervention: Non-TEVAR medical treatment
Description: Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.

Intervention type: OTHER
Intervention: Non-TEVAR medical treatment
Description: Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
Study: NCT03123627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New profilaxis
Description: Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profilaxis recommended
Description: Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
Study: NCT03959306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Seed Oil
Description: Black seed oil soft gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Diabetics
Description: standard anti-diabetic treatment prescribed for the patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Diabetics
Description: standard anti-diabetic treatment prescribed for the patient
Study: NCT03752021

Intervention type: PROCEDURE
Intervention: Myometrial Sampling
Description: A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review
Study: NCT03960502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-881
Description: Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C315N3]AG-881
Description: Single IV microdose of approximately 100 μg.
Study: NCT00750854

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM Formulation X
Description: see Treatment Arms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM Formulation Y
Description: see Treatment Arms
Study: NCT01050738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position of catheter
Description: Position of catheter for administration of local anestesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position of catheter
Description: Position of catheter for administration of local anestesia.
Study: NCT01852292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buparlisib matching Placebo
Description: Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
Study: NCT02586012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
Study: NCT00741884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 1.2 mg
Description: Varenicline CR tablet 1.2 mg BID for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 1.8 mg
Description: Varenicline CR tablet 1.8 mg BID for 7 weeks
Study: NCT02738554

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment cessation
Description: Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
Study: NCT02728089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
Description: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
Study: NCT00741884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Controlled Release 2.4 mg
Description: Varenicline CR tablet 2.4 mg BID for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Immediate Release 1 mg
Description: Varenicline IR tablet 1 mg BID for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 7 weeks
Study: NCT00003256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study: NCT02226276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fludeoxyglucose F 18 PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: Given IV
Study: NCT02521922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - NEHB Configuration
Description: VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - PAL Configuration
Description: VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
Study: NCT03674632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation meditation tape
Description: The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
Study: NCT04083365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 5040 cGy radiotherapy for 5 days per week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
Study: NCT01180686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator IV single impulse instrument
Description: This is a manually operated device that delivers a single thrust into the joint involved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple thrust Impulse adjusting instrument
Description: A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
Study: NCT03796117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Russian Current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Russian Current
Description: For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used.
Study: NCT04327570

Intervention type: OTHER
Intervention: Patient sampling
Description: Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
Study: NCT02226276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo copper Cu-DOTA-trastuzumab PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01813760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illuiminage ® Diode Laser
Description: Diode laser for treatment of peri-orbital and peri-oral wrinkles
Study: NCT04167774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
Study: NCT02951143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes
Description: Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECTRUM cigarettes between
Description: Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
Study: NCT02220829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive administration of Rapaflo
Description: Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Administration of alpha-blocker Rapaflo only at onset of symptoms.
Study: NCT03575728

Intervention type: OTHER
Group type: OTHER
Intervention: MyChart-MHT
Description: All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm

Intervention type: OTHER
Group type: OTHER
Intervention: MyChart-MHT
Description: All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
Study: NCT00994526

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ham
Description: Ham : 180 g per day during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ham + calcium
Description: Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ham + vitamin E
Description: Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
Study: NCT04382885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Solution
Study: NCT04167774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nb-Paclitaxel
Description: nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
Study: NCT04382885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Solution
Study: NCT00634348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
Study: NCT03565536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar
Description: for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operation
Description: If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiation therapy
Description: As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
Study: NCT01068574

Intervention type: OTHER
Intervention: BASIC Score (Observational)
Description: The BASIC Score will be assessed by a study staff, but there are no interventions.
Study: NCT03822767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-bOPV vaccination schedule
Description: Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV-wIPV-bOPV vaccination schedule
Description: Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
Study: NCT02701153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies